190 related articles for article (PubMed ID: 37863651)
21. Synthetic lethal genetic screens in Ras mutant cancers.
Yu B; Luo J
Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
[TBL] [Abstract][Full Text] [Related]
22. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
23. Defeat mutant KRAS with synthetic lethality.
Pang X; Liu M
Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
[TBL] [Abstract][Full Text] [Related]
24. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
Anderson GR; Winter PS; Lin KH; Nussbaum DP; Cakir M; Stein EM; Soderquist RS; Crawford L; Leeds JC; Newcomb R; Stepp P; Yip C; Wardell SE; Tingley JP; Ali M; Xu M; Ryan M; McCall SJ; McRee AJ; Counter CM; Der CJ; Wood KC
Cell Rep; 2017 Jul; 20(4):999-1015. PubMed ID: 28746882
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
26. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
Lee SK; Hwang JH; Choi KY
Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
[TBL] [Abstract][Full Text] [Related]
27. Mathematical modeling the order of driver gene mutations in colorectal cancer.
Li L; Hu Y; Xu Y; Tang S
PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
[TBL] [Abstract][Full Text] [Related]
28. Combined Mutation of
Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
[TBL] [Abstract][Full Text] [Related]
29. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.
Fan F; Ghosh S; Powell R; Roszik J; Park Y; Sobieski M; Sorokin A; Stephan C; Kopetz S; Ellis LM; Bhattacharya R
PLoS One; 2023; 18(3):e0281063. PubMed ID: 36952536
[TBL] [Abstract][Full Text] [Related]
30. Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib.
Wu CS; Wu SY; Chen HC; Chu CA; Tang HH; Liu HS; Hong YR; Huang CF; Huang GC; Su CL
J Nutr Biochem; 2019 Dec; 74():108227. PubMed ID: 31675556
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
32. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C; Fröhling S; Dunn IF; Schinzel AC; Barbie DA; Kim SY; Silver SJ; Tamayo P; Wadlow RC; Ramaswamy S; Döhner K; Bullinger L; Sandy P; Boehm JS; Root DE; Jacks T; Hahn WC; Gilliland DG
Cell; 2009 May; 137(5):821-34. PubMed ID: 19490892
[TBL] [Abstract][Full Text] [Related]
34. Strategies for Targeting KRAS: A Challenging Drug Target.
Wadood A; Ajmal A; Rehman AU
Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
[TBL] [Abstract][Full Text] [Related]
35. Exploring Candidate Human Synthetic Lethal Interactions Through siRNA and Quantitative Imaging-Based Approaches.
Jeusset LM; McManus KJ
Methods Mol Biol; 2021; 2381():151-173. PubMed ID: 34590275
[TBL] [Abstract][Full Text] [Related]
36. Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens.
Montazeri H; Coto-Llerena M; Bianco G; Zangene E; Taha-Mehlitz S; Paradiso V; Srivatsa S; de Weck A; Roma G; Lanzafame M; Bolli M; Beerenwinkel N; von Flüe M; Terracciano LM; Piscuoglio S; Ng CKY
Nucleic Acids Res; 2021 Sep; 49(15):8488-8504. PubMed ID: 34313788
[TBL] [Abstract][Full Text] [Related]
37. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
Spreafico A; Tentler JJ; Pitts TM; Tan AC; Gregory MA; Arcaroli JJ; Klauck PJ; McManus MC; Hansen RJ; Kim J; Micel LN; Selby HM; Newton TP; McPhillips KL; Gustafson DL; Degregori JV; Messersmith WA; Winn RA; Eckhardt SG
Clin Cancer Res; 2013 Aug; 19(15):4149-62. PubMed ID: 23757356
[TBL] [Abstract][Full Text] [Related]
38. Clinical validation of coexisting driver mutations in colorectal cancers.
Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
40. Extended-spectrum of
Basdemirci M; Zamani A; Zamani AG; Findik S; Yildirim MS
Indian J Cancer; 2022; 59(2):236-243. PubMed ID: 34380837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
